By VETTAPHARMA reporter – Derek Roche: Takeda has revised its fiscal year 2025 earnings report to reflect the financial impact of the recent U.S. jury verdict in the AMITIZA® (lubiprostone) antitrust litigation. The updated filing incorporates changes to the company’s consolidated financial statements for the fiscal year ended March 31, 2026.
Following its assessment of the verdict, Takeda recorded an additional provision for legal proceedings of JPY 402.5 billion and recognized related tax benefits of JPY 58.4 billion in its FY2025 consolidated financial statements.
The company emphasized that the revision does not affect its Core financial results for FY2025. Takeda also maintained its previously issued FY2026 financial forecast and Management Guidance, including its outlook for adjusted free cash flow.
Shareholder returns remain unchanged. Takeda confirmed that the FY2025 year-end dividend will remain JPY 100 per share, while the FY2026 annual dividend forecast remains JPY 204 per share.
Commenting on the update, Chief Financial Officer Milano Furuta said the jury verdict resulted in the recognition of legal provisions in reported earnings but does not alter the company’s underlying business momentum or its outlook for FY2026. Furuta highlighted Takeda’s planned launches over the next 12 months and the company’s late-stage development pipeline as drivers of future growth.
Takeda stated that the amount of any ultimate liability arising from the AMITIZA litigation has not yet been finalized. The company plans to vigorously pursue post-trial motions and an appeal and will seek a stay of execution of any judgment while appellate proceedings are ongoing.
According to Takeda, it does not expect the litigation proceedings to materially impact its FY2026 financial forecast or Management Guidance. The company said it will continue evaluating developments in the case, including an expected district court judgment during the second half of calendar year 2026, and will provide updates as appropriate.
Quick FAQs
1. What Is AMITIZA®?
AMITIZA® (lubiprostone) is a prescription medication approved for certain constipation-related gastrointestinal disorders and is the product at the center of the U.S. antitrust litigation referenced in Takeda’s financial update.
2. What Did Takeda Announce?
Takeda revised its FY2025 earnings report to reflect the impact of the AMITIZA antitrust jury verdict on its consolidated financial statements.
3. What Is the Litigation?
The matter involves AMITIZA® antitrust litigation in the United States. Further details regarding the underlying claims were not disclosed in the provided source.
4. What Financial Changes Were Reported?
Takeda recorded an additional legal provision of JPY 402.5 billion and recognized related tax benefits of JPY 58.4 billion in FY2025 results.
5. What Were the Key Financial Guidance Updates?
There were no changes to FY2026 financial forecasts, Management Guidance, adjusted free cash flow guidance, FY2025 year-end dividend of JPY 100 per share, or FY2026 annual dividend forecast of JPY 204 per share.
6. Why Is This Important?
The update reflects a significant litigation-related accounting charge while indicating that Takeda’s core FY2025 performance, FY2026 outlook, dividend plans, and long-term growth strategy remain unchanged.
